Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Table 4 Multivariate Cox regression models for major adverse cardiac events and target lesion failure

	Hazard ratio	Lower 95% CI	Higher 95% CI	p-value
A. Variable for outcome MACE
Gender—female vs. male	1.78	0.58	5.45	0.31
Age at device implantation	1.02	0.98	1.07	0.39
PCI-indication—ACS vs. non-ACS	0.67	0.27	1.62	0.37
Insulin-treated DM—no vs. yes	2.01	0.80	5.04	0.14
B1. Variable for outcome TLF
Gender—female vs. male	3.44	0.76	15.47	0.11
Age at device implantation	1.03	0.98	1.09	0.27
PCI-indication—ACS vs. non-ACS	0.61	0.22	1.65	0.33
Insulin-treated DM—no vs. yes	2.54	0.93	6.97	0.07
B2. Variable for outcome TLF
Gender—female vs. male	2.87	0.65	12.69	0.17
Age at device implantation	1.03	0.97	1.09	0.32
PCI-indication—ACS vs. non-ACS	0.64	0.24	1.74	0.39
Postdilatation performed—no vs. yes	0.40	0.15	1.07	0.07

Section A. Multivariate Cox regression model for major adverse cardiac events adjusted with age, gender, PCI-indication and diabetes mellitus treated with insulin at hospital admission. Section B. The same model calculated for target lesion failure (B1) and a model with incorporation of postdilatation (B2). Risk factors are given in hazard ratio’s with 95% confidence intervals with corresponding p-values. A p-value < 0.05 was uphold as formally statistical significant. Insulin-treated diabetes mellitus was identified as variable that showed a trend towards a predictor for major adverse cardiac events. Insulin-treated diabetes mellitus and absence of postdilatation were identified as variables that showed a trend towards a predictor for target lesion failure
MACE major adverse cardiac events, CI confidence interval, PCI percutaneous coronary intervention, ACS acute coronary syndrome, DM diabetes mellitus, TLF target lesion failure

ISSN: 1475-2840